These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 16603352)

  • 21. Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation.
    Yan W; Wang X; Dai Y; Zhao B; Yang X; Fan J; Gao Y; Meng F; Wang Y; Luo C; Ai J; Geng M; Duan W
    J Med Chem; 2016 Jul; 59(14):6690-708. PubMed ID: 27348537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 7-[1H-Indol-2-yl]-2,3-dihydro-isoindol-1-ones as dual Aurora-A/VEGF-R2 kinase inhibitors: design, synthesis, and biological activity.
    Hughes TV; Emanuel SL; O'Grady HR; Connolly PJ; Rugg C; Fuentes-Pesquera AR; Karnachi P; Alexander R; Middleton SA
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5130-3. PubMed ID: 18718756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors.
    Cole AG; Bohnstedt AC; Paradkar V; Kingsbury C; Quintero JG; Park H; Lu Y; You M; Neagu I; Diller DJ; Letourneau JJ; Shao Y; James RA; Riviello CM; Ho KK; Lin TH; Wang B; Appell KC; Sills M; Quadros E; Kimble EF; Ohlmeyer MH; Webb ML
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6788-92. PubMed ID: 19836234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.
    Bauer D; Whittington DA; Coxon A; Bready J; Harriman SP; Patel VF; Polverino A; Harmange JC
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4844-8. PubMed ID: 18682324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
    Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors.
    Renhowe PA; Pecchi S; Shafer CM; Machajewski TD; Jazan EM; Taylor C; Antonios-McCrea W; McBride CM; Frazier K; Wiesmann M; Lapointe GR; Feucht PH; Warne RL; Heise CC; Menezes D; Aardalen K; Ye H; He M; Le V; Vora J; Jansen JM; Wernette-Hammond ME; Harris AL
    J Med Chem; 2009 Jan; 52(2):278-92. PubMed ID: 19113866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors.
    Hasegawa M; Nishigaki N; Washio Y; Kano K; Harris PA; Sato H; Mori I; West RI; Shibahara M; Toyoda H; Wang L; Nolte RT; Veal JM; Cheung M
    J Med Chem; 2007 Sep; 50(18):4453-70. PubMed ID: 17676829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2-Aminobenzimidazoles as potent ITK antagonists: trans-stilbene-like moieties targeting the kinase specificity pocket.
    Lo HY; Bentzien J; Fleck RW; Pullen SS; Khine HH; Woska JR; Kugler SZ; Kashem MA; Takahashi H
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6218-21. PubMed ID: 18930400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
    Hu C; Solomon VR; Ulibarri G; Lee H
    Bioorg Med Chem; 2008 Sep; 16(17):7888-93. PubMed ID: 18691894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
    Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic.
    Combs AP; Zhu W; Crawley ML; Glass B; Polam P; Sparks RB; Modi D; Takvorian A; McLaughlin E; Yue EW; Wasserman Z; Bower M; Wei M; Rupar M; Ala PJ; Reid BM; Ellis D; Gonneville L; Emm T; Taylor N; Yeleswaram S; Li Y; Wynn R; Burn TC; Hollis G; Liu PC; Metcalf B
    J Med Chem; 2006 Jun; 49(13):3774-89. PubMed ID: 16789735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benzimidazoles as non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 3: Discovery of 1-(1H-benzimidazol-5-yl)-3-tert-butylurea derivatives.
    Tatsuta M; Kataoka M; Yasoshima K; Sakakibara S; Shogase Y; Shimazaki M; Yura T; Li Y; Yamamoto N; Gupta J; Urbahns K
    Bioorg Med Chem Lett; 2005 May; 15(9):2265-9. PubMed ID: 15837306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis of 2-aryl-4-(benzimidazol-2-yl)-1,2-dihydro[1,2,4]triazino-[4,5-a]benzimidazol-1-one derivatives with preferential cytotoxicity against carcinoma cell lines.
    Stýskala J; Stýskalová L; Slouka J; Hajdúch M
    Eur J Med Chem; 2008 Mar; 43(3):449-55. PubMed ID: 18272255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
    Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM
    J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk).
    Moriarty KJ; Takahashi H; Pullen SS; Khine HH; Sallati RH; Raymond EL; Woska JR; Jeanfavre DD; Roth GP; Winters MP; Qiao L; Ryan D; DesJarlais R; Robinson D; Wilson M; Bobko M; Cook BN; Lo HY; Nemoto PA; Kashem MA; Wolak JP; White A; Magolda RL; Tomczuk B
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5545-9. PubMed ID: 18819799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
    Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
    Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1-[(Imidazolidin-2-yl)imino]indazole. Highly alpha 2/I1 selective agonist: synthesis, X-ray structure, and biological activity.
    Saczewski F; Kornicka A; Rybczyńska A; Hudson AL; Miao SS; Gdaniec M; Boblewski K; Lehmann A
    J Med Chem; 2008 Jun; 51(12):3599-608. PubMed ID: 18517187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 4-(1H-indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors.
    Shafer CM; Lindvall M; Bellamacina C; Gesner TG; Yabannavar A; Jia W; Lin S; Walter A
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4482-5. PubMed ID: 18672368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.
    Laufer R; Forrest B; Li SW; Liu Y; Sampson P; Edwards L; Lang Y; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Beletskaya I; Mason JM; Luo X; Wei X; Yao Y; Feher M; Ban F; Kiarash R; Green E; Mak TW; Pan G; Pauls HW
    J Med Chem; 2013 Aug; 56(15):6069-87. PubMed ID: 23829549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.